New approaches to the understanding of tamoxifen action and resistance.
about
Endocrinology and hormone therapy in breast cancer: aromatase inhibitors versus antioestrogensAdaptation to estradiol deprivation causes up-regulation of growth factor pathways and hypersensitivity to estradiol in breast cancer cells.Long-term exposure to dietary sources of genistein induces estrogen-independence in the human breast cancer (MCF-7) xenograft model.Delineation of a FOXA1/ERα/AGR2 regulatory loop that is dysregulated in endocrine therapy-resistant breast cancer.Combinational treatment of gap junctional activator and tamoxifen in breast cancer cells.What do we know about the mechanisms of aromatase inhibitor resistance?A phase II trial of capecitabine in combination with the farnesyltransferase inhibitor tipifarnib in patients with anthracycline-treated and taxane-resistant metastatic breast cancer: an Eastern Cooperative Oncology Group Study (E1103).Proteomic analysis of acquired tamoxifen resistance in MCF-7 cells reveals expression signatures associated with enhanced migration.Mechanisms of resistance to endocrine therapy in breast cancer: focus on signaling pathways, miRNAs and genetically based resistance.Phase II trial of the farnesyltransferase inhibitor tipifarnib plus fulvestrant in hormone receptor-positive metastatic breast cancer: New York Cancer Consortium Trial P6205.Lead optimization of COX-2 inhibitor nimesulide analogs to overcome aromatase inhibitor resistance in breast cancer cells.Isolated and combined action of tamoxifen and metformin in wild-type, tamoxifen-resistant, and estrogen-deprived MCF-7 cells.Oestrogen treatment enhances the sensitivity of hormone-resistant breast cancer cells to doxorubicin.Upregulation of PKC-delta contributes to antiestrogen resistance in mammary tumor cells.A novel antiestrogenic mechanism in progesterone receptor-transfected breast cancer cells.Horizontal Transfer of Tamoxifen Resistance in MCF-7 Cell Derivates: Proteome Study.Cancer endocrinology through own experience: areas for further thought and development. Interview by Natasha Galukande.Molecular mechanisms of hormone resistance of breast cancer.
P2860
Q24796233-C93D6876-F930-4C83-BF7F-355B5725092DQ30440238-8123A00D-69EF-4057-A92C-FD4A132794CEQ34084662-58FC51B7-2B69-4CA6-82EC-683B05F6D9F8Q34747157-D428133E-7707-4C13-8CAE-9C64DE48AB7FQ35230023-B62F15DA-3345-4E9C-B5CA-C1AED891F578Q35691554-47519E26-EFC2-4D43-9F6C-D78B8737F83EQ36132957-498D4DF3-9929-4E14-BF2B-BB9DBA95A2F0Q36245528-7B80C879-3E9C-4531-AB93-7A93472372C3Q36589865-CF2544C2-AF9B-4ADA-B30E-104D7C58D1EBQ37140318-ECAF8907-F913-41E7-8CE8-4FDA54DF5A9DQ37440937-23729BFB-B5D4-48E9-A36D-0E003F5E2B4CQ39671678-D0FC0560-93A2-4FDB-81FC-470CB9F146EDQ39675249-BB0325E1-8942-4BF1-9F29-F0F78A2A7F96Q40453538-0D6836EF-33D2-4336-8405-A95D9335AFCFQ40455238-AF87E7D1-C521-4C84-A60D-F723EF9522D4Q47802521-2860A454-B015-462A-9060-5EB94FEB6A3EQ48210184-A850708F-BDD2-4C09-9671-7CCF1878B951Q53086084-D4DEADCB-F474-428B-A8C9-CFA1948B0B15
P2860
New approaches to the understanding of tamoxifen action and resistance.
description
2003 nî lūn-bûn
@nan
2003 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
New approaches to the understanding of tamoxifen action and resistance.
@ast
New approaches to the understanding of tamoxifen action and resistance.
@en
type
label
New approaches to the understanding of tamoxifen action and resistance.
@ast
New approaches to the understanding of tamoxifen action and resistance.
@en
prefLabel
New approaches to the understanding of tamoxifen action and resistance.
@ast
New approaches to the understanding of tamoxifen action and resistance.
@en
P2093
P356
P1476
New approaches to the understanding of tamoxifen action and resistance.
@en
P2093
Berstein LM
Lykkesfeldt AE
Naftolin F
Shanabrough M
P304
P356
10.1677/ERC.0.0100267
P577
2003-06-01T00:00:00Z